Ferring’s Fecal Transplant Gets Through AdComm, Aided By Preference For Standardized Product

 
• By Sarah Karlin-Smith

US FDA's Vaccines and Related Biological Products Advisory Committee endorses Rebyota for recurrent C. difficile infection; most panelists prefer a product whose manufacturing will be regulated, even one with lingering concerns about efficacy or safety, over the current landscape.

How Rebyota might change the regulatory landscape for unapproved fecal transplants was among the advisory committee's considerations. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers